Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.
Einsiedler M, Sandgren S, Schaedelin S, Ning K, Maleska Maceski A, Oechtering J, Cordano C, Melie-Garcia L, Gelfand JM, Cagol A, Henry RG, Finkener S, Lalive PH, Müller S, Pot C, Mathias A, Du Pasquier R, Hoepner R, Chan A, Disanto G, Zecca C, D'Souza M, Hemkens LG, Yaldizli Ö, Fischer-Barnicol B, Derfuss T, Roth P, Herwerth M, Gobbi C, Brassat D, Tackenberg B, Pedotti R, Wiendl H, Berger K, Hermesdorf M, Arrambide G, Piehl F, Zetterberg H, Cree BAC, Sormani MP, Kappos L, Hauser SL, Khalil M, Granziera C, Green AJ, Leppert D, Benkert P, Abdelhak A, Kuhle J; Expression, Proteomics, Imaging, Clinical (EPIC) study and the Swiss MS Cohort (SMSC) investigators; Hofer L, Hughes M, Genc N, Zadic A, Vilchez Gomez JF, Galbusera R, Galli E, Müller J, Uginet M, Kana V, Raposo C, Oksenberg J, Conen D.
Einsiedler M, et al. Among authors: oksenberg j.
JAMA Neurol. 2026 Aug 3:e262500. doi: 10.1001/jamaneurol.2026.2500. Online ahead of print.
JAMA Neurol. 2026.
PMID: 42545715